Evaluating laser therapy for treating advanced periodontal disease
Clinical and Microbiological Evaluation of Laser Therapy in the Treatment of Periodontal Disease in Stages III and IV
This study tests if adding laser therapy to regular treatment can help people with advanced gum disease feel better and improve their oral health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Universidade Federal Fluminense Academic / other |
| Locations | 1 site (Nova Friburgo, Rio de Janeiro) |
| Trial ID | NCT06426550 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the effectiveness of photodynamic therapy and photobiomodulation in treating periodontitis. Participants will receive conventional periodontal treatment combined with laser therapy and methylene blue to enhance clinical and microbiological outcomes. The study will involve twenty patients with advanced stages of periodontal disease, comparing results between those receiving the treatment and a placebo group. Clinical parameters such as plaque index, bleeding on probing, and probing depth will be measured at baseline and three months post-treatment.
Who should consider this trial
Good fit: Ideal candidates are adults with generalized periodontitis in stages III and IV, exhibiting severe periodontal issues.
Not a fit: Patients who have received periodontal treatment in the last six months or have systemic conditions that may interfere with the study will not benefit.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with advanced periodontal disease.
How similar studies have performed: Previous studies have shown promising results with laser therapy in periodontal treatment, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult participants with periodontal disease; * Four or more periodontal sites with PPD≥6 mm and CAL≥5 mm, non-adjacent; * Generalized periodontitis, with more than 30% of the sites involved (Caton et al., 2018); * Stages III and IV of periodontal disease (Caton et al., 2018); Exclusion Criteria: * Participants with hypersensitivity to the components of the 0.005% methylene blue gel; * Received periodontal treatment in the last six months; * Drugs (alcoholics, use of anti-inflammatories and antibiotics in the last 3 months); Any evidence of systemic modifying factors which may directly interfere with the completion of the work (bias), such as: * Pregnant and breastfeeding women; * Hormone replacement therapy; * Smoking; * Hyperglycemia; * Osteoporosis; * Diagnosed with HIV+ or AIDS.
Where this trial is running
Nova Friburgo, Rio de Janeiro
- Fluminense Federal University — Nova Friburgo, Rio de Janeiro, Brazil (Recruiting)
Study contacts
- Principal investigator: Gabriela AC Camargo, Doctor — Fluminense Federal University
- Study coordinator: Gabriela AC Camargo, PhD
- Email: gabrielacruz@id.uff.br
- Phone: 12981815874
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.